Arvinas (ARVN) Current Deferred Revenue (2017 - 2026)
Arvinas' (ARVN) quarterly Current Deferred Revenue came in at $51.8 million in Q1 2026, down 80.03% year-on-year from $259.4 million in Q1 2025, and down 74.81% quarter-over-quarter from $205.6 million in Q4 2025.
Arvinas (ARVN) Current Deferred Revenue (2017 - 2026) Analysis & Trends
Arvinas' Current Deferred Revenue history runs 10 years deep, the most recent figure standing at $51.8 million for Q1 2026.
- On a quarterly basis, Current Deferred Revenue fell 80.03% year-over-year to $51.8 million in Q1 2026; TTM through Mar 2026 was $51.8 million, a 80.03% decrease from a year earlier, with the FY2025 full-year figure at $205.6 million, down 54.13% from the prior year.
- Current Deferred Revenue eased to $51.8 million in Q1 2026 per ARVN's latest filing, from $205.6 million in the prior quarter.
- Across five years, Current Deferred Revenue topped out at $719.4 million in Q1 2022 and bottomed at $51.8 million in Q1 2026.
- The 5-year median for Current Deferred Revenue is $523.9 million (2024), against an average of $458.1 million.
- Across the five-year window, Current Deferred Revenue surged 1759.46% in 2022 and slumped 82.83% in 2025, its largest moves.
- Year by year, Current Deferred Revenue stood at $623.7 million in 2022, then fell by 11.94% to $549.2 million in 2023, then retreated by 18.39% to $448.2 million in 2024, then tumbled by 54.13% to $205.6 million in 2025, then plunged by 74.81% to $51.8 million in 2026.
- Per Business Quant, the three latest ARVN Current Deferred Revenue figures stand at $51.8 million (Q1 2026), $205.6 million (Q4 2025), and $215.1 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Arvinas | 519.68 Mn | -95.22 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 51.80 Mn |
| Dec 31, 2025 | 205.60 Mn |
| Sep 30, 2025 | 215.10 Mn |
| Jun 30, 2025 | 102.90 Mn |
| Mar 31, 2025 | 259.40 Mn |
| Dec 31, 2024 | 448.20 Mn |
| Sep 30, 2024 | 503.70 Mn |
| Jun 30, 2024 | 599.20 Mn |
| Mar 31, 2024 | 523.90 Mn |
| Dec 31, 2023 | 549.20 Mn |
| Sep 30, 2023 | 506.10 Mn |
| Jun 30, 2023 | 540.60 Mn |
| Mar 31, 2023 | 593.80 Mn |
| Dec 31, 2022 | 623.70 Mn |
| Sep 30, 2022 | 657.70 Mn |
| Jun 30, 2022 | 688.00 Mn |
| Mar 31, 2022 | 719.40 Mn |
| Dec 31, 2021 | 740.50 Mn |
| Sep 30, 2021 | 763.40 Mn |
| Jun 30, 2021 | 37.00 Mn |